Effectiveness of JAK inhibitors in biologics-naïve patients with RA: a population-based study
Our findings reflected drug effectiveness by the duration that patients maintained the regimen, considering both therapeutic effects and adverse events. We found JAK inhibitors had better effectiveness than TNFi biologics, with no significant difference compared with non-TNFi biologics in biologics-naïve patients. Intra-class comparison of JAK inhibitors indicated similar effectiveness for both tofacitinib and baricitinib. These findings supported the use of JAK inhibitors in RA patients after failure of conventional DMARDs treatment.
Authors
- Anthony Chuang
- Edward Chia‐Cheng Lai (ORCID: https://orcid.org/0000-0002-5852-7652)
- Daniel Hsiang‐Te Tsai (ORCID: https://orcid.org/0000-0003-2841-0338)
- Huei‐Kai Huang (ORCID: https://orcid.org/0000-0003-3612-653X)
- Meng‐Yu Weng (ORCID: https://orcid.org/0000-0002-0741-2134)
Institutions
- Tzu Chi University (TW)
- Tzu Chi Foundation (TW)
- University Medical Center (US)
- Buddhist Tzu Chi Medical Foundation (US)
- Pharmac (NZ)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1093/rheumatology/keaf216
- Citations
- 1
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.67
Funders
- National Health Research Institutes